For Psoriasis, Ustekinumab & TNF Inhibitors Show Similar Cardiac Safety

NEW YORK (Reuters Health)—In patients with psoriatic disease, the incidence of atrial fibrillation and major adverse cardiovascular events does not differ between treatment with ustekinumab and TNF inhibitors, according to a large observational study. “Given a high cardiovascular risk among patients with psoriasis and psoriatic arthritis,” Seoyoung C. Kim, MD, ScD, MSCE, told Reuters Health... [Read More]
Source: The Rheumatologist - Category: Rheumatology Authors: Tags: Conditions cardiovascular cardiovascular event Psoratic Arthritis Psoriasis Safety TNF inhibitor ustekinumab Source Type: research